Evidence map›Paper›PMID 37609429›Full record

ArticleHeliyon2023

Leyla Blanco-García, Yolanda Ruano, Raquel Blanco Martínez-Illescas, Rocío Cubo, Paula Jiménez Sánchez, Víctor J Sánchez-Arévalo Lobo, Erica Riveiro Falkenbach, Pablo Ortiz Romero, María C Garrido, José L Rodríguez Peralto

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Leyla Blanco-GarcíaResearch Institute 12 de Octubre Hospital, Madrid, Spain.
Yolanda RuanoResearch Institute 12 de Octubre Hospital, Madrid, Spain.
Raquel Blanco Martínez-IllescasResearch Institute 12 de Octubre Hospital, Madrid, Spain.
Rocío CuboResearch Institute 12 de Octubre Hospital, Madrid, Spain.
Paula Jiménez SánchezResearch Institute 12 de Octubre Hospital, Madrid, Spain.
Víctor J Sánchez-Arévalo LoboResearch Institute 12 de Octubre Hospital, Madrid, Spain.
Erica Riveiro FalkenbachResearch Institute 12 de Octubre Hospital, Madrid, Spain.
Pablo Ortiz RomeroDepartment of Dermatology, 12 de Octubre University Hospital, Madrid, Spain.
María C GarridoDepartment of Pathology, 12 de Octubre University Hospital, Madrid, Spain.
José L Rodríguez PeraltoDepartment of Pathology, 12 de Octubre University Hospital, Madrid, Spain.
Research Institute Hospital 12 de Octubre · ESUniversidad Francisco de Vitoria · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is the most aggressive form of skin cancer and the leading cause of death from cutaneous tumors. Several studies have associated alterations in the

Indexed as

BiomarkerCirculating free DNAMelanomaTERT promoter methylationTERT promoter mutations

Identifiers

PMID37609429
PMCPMC10440525
OpenAlexW4385612924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.